NYSE:ZYME - Zymeworks Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $12.80 +0.03 (+0.23 %) (As of 12/18/2018 11:57 AM ET)Previous Close$12.77Today's Range$12.78 - $12.9252-Week Range$7.26 - $29.00Volume2,530 shsAverage Volume126,651 shsMarket Capitalization$450.73 millionP/E Ratio-22.51Dividend YieldN/ABeta3.71 ProfileDiscussionAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Zymeworks Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of bio-therapeutics for the treatment of cancer in Canada. The company's lead product candidate is ZW25, a novel bispecific antibody that is in Phase I clinical trial for the treatment of breast and gastric cancer. It is also developing ZW49, a bispecific antibody-drug conjugate that is in IND application stage. The company has strategic partnerships with Merck Sharp & Dohme Research Ltd.; Eli Lilly and Company; Celgene Corporation and Celgene Alpine Investment Co. LLC; GlaxoSmithKline Intellectual Property Development Limited; Daiichi Sankyo Co., Ltd.; and Janssen Biotech, Inc., as well as a collaboration agreement with Celgene Corporation. It also has licensing and research collaboration with LEO Pharma A/S to discover and develop bispecific antibodies targeting cytokine-receptor pathways. Zymeworks Inc. was founded in 2003 and is headquartered in Vancouver, Canada. Receive ZYME News and Ratings via Email Sign-up to receive the latest news and ratings for ZYME and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NYSE Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNYSE:ZYME Previous SymbolNASDAQ:ZYME CUSIPN/A Webwww.zymeworks.com Phone604-678-1388 Debt Debt-to-Equity RatioN/A Current Ratio6.42 Quick Ratio6.42 Price-To-Earnings Trailing P/E Ratio-22.51 Forward P/E Ratio-5.66 P/E GrowthN/A Sales & Book Value Annual Sales$51.76 million Price / Sales7.91 Cash FlowN/A Price / Cash FlowN/A Book Value$4.59 per share Price / Book2.79 Profitability EPS (Most Recent Fiscal Year)($0.57) Net Income$-10,400,000.00 Net Margins-17.66% Return on Equity-9.24% Return on Assets-8.05% Miscellaneous Employees147 Outstanding Shares31,970,000Market Cap$450.73 million OptionableOptionable Zymeworks (NYSE:ZYME) Frequently Asked Questions What is Zymeworks' stock symbol? Zymeworks trades on the New York Stock Exchange (NYSE) under the ticker symbol "ZYME." How were Zymeworks' earnings last quarter? Zymeworks Inc (NYSE:ZYME) issued its quarterly earnings data on Tuesday, November, 6th. The company reported ($0.59) earnings per share for the quarter, beating analysts' consensus estimates of ($0.67) by $0.08. The firm earned $2.05 million during the quarter, compared to analyst estimates of $2 million. Zymeworks had a negative return on equity of 9.24% and a negative net margin of 17.66%. View Zymeworks' Earnings History. When is Zymeworks' next earnings date? Zymeworks is scheduled to release their next quarterly earnings announcement on Wednesday, March 13th 2019. View Earnings Estimates for Zymeworks. What price target have analysts set for ZYME? 6 Wall Street analysts have issued 12 month price objectives for Zymeworks' shares. Their predictions range from $15.00 to $37.00. On average, they anticipate Zymeworks' stock price to reach $24.3333 in the next year. This suggests a possible upside of 89.8% from the stock's current price. View Analyst Price Targets for Zymeworks. What is the consensus analysts' recommendation for Zymeworks? 6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Zymeworks in the last year. There are currently 1 hold rating and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Zymeworks. Has Zymeworks been receiving favorable news coverage? Press coverage about ZYME stock has trended negative on Tuesday, InfoTrie Sentiment Analysis reports. InfoTrie identifies positive and negative press coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Zymeworks earned a daily sentiment score of -2.4 on InfoTrie's scale. They also assigned news articles about the company a news buzz of 5.0 out of 10, meaning that recent press coverage is somewhat likely to have an effect on the company's share price in the near future. Who are some of Zymeworks' key competitors? Some companies that are related to Zymeworks include Reata Pharmaceuticals (RETA), Zogenix (ZGNX), Innoviva (INVA), Madrigal Pharmaceuticals (MDGL), PTC Therapeutics (PTCT), Prestige Consumer Healthcare (PBH), Mallinckrodt (MNK), Biohaven Pharmaceutical (BHVN), Theravance Biopharma (TBPH), Wave Life Sciences (WVE), Enanta Pharmaceuticals (ENTA), The Medicines (MDCO), Cambrex (CBM), Vanda Pharmaceuticals (VNDA) and Zai Lab (ZLAB). Who are Zymeworks' key executives? Zymeworks' management team includes the folowing people: Dr. Ali Tehrani, Co-Founder, Pres, CEO & Director (Age 46)Mr. Neil Klompas C.A., CPA, CPA, CA, Chief Financial Officer (Age 46)Dr. Diana F. Hausman, Chief Medical Officer (Age 55)Dr. Donald L. Drakeman Ph.D., J.D., Special Advisor (Age 64)Dr. Surjit Dixit, VP of Technology (Age 45) When did Zymeworks IPO? (ZYME) raised $65 million in an initial public offering (IPO) on Friday, April 28th 2017. The company issued 4,500,000 shares at a price of $13.00-$16.00 per share. Citigroup, Barclays, Wells Fargo Securities and Canaccord Genuity acted as the underwriters for the IPO and Cormark Securities was co-manager. Who are Zymeworks' major shareholders? Zymeworks' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Franklin Resources Inc. (2.25%), Renaissance Technologies LLC (1.18%), Wedge Capital Management L L P NC (0.50%), Vident Investment Advisory LLC (0.45%), Point72 Asset Management L.P. (0.36%) and Wells Fargo & Company MN (0.28%). View Institutional Ownership Trends for Zymeworks. Which institutional investors are selling Zymeworks stock? ZYME stock was sold by a variety of institutional investors in the last quarter, including Laurion Capital Management LP, Franklin Resources Inc. and Vident Investment Advisory LLC. View Insider Buying and Selling for Zymeworks. Which institutional investors are buying Zymeworks stock? ZYME stock was acquired by a variety of institutional investors in the last quarter, including Acadian Asset Management LLC, Stanley Laman Group Ltd., Wells Fargo & Company MN, Renaissance Technologies LLC, Point72 Asset Management L.P., Granite Investment Partners LLC, Wedge Capital Management L L P NC and K.J. Harrison & Partners Inc. View Insider Buying and Selling for Zymeworks. How do I buy shares of Zymeworks? Shares of ZYME can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Zymeworks' stock price today? One share of ZYME stock can currently be purchased for approximately $12.82. How big of a company is Zymeworks? Zymeworks has a market capitalization of $450.73 million and generates $51.76 million in revenue each year. The company earns $-10,400,000.00 in net income (profit) each year or ($0.57) on an earnings per share basis. Zymeworks employs 147 workers across the globe. What is Zymeworks' official website? The official website for Zymeworks is http://www.zymeworks.com. How can I contact Zymeworks? Zymeworks' mailing address is 1385 West 8th Avenue Suite 540, Vancouver A1, V6H 3V9. The company can be reached via phone at 604-678-1388 or via email at [email protected] MarketBeat Community Rating for Zymeworks (NYSE ZYME)Community Ranking: 2.8 out of 5 ( )Outperform Votes: 131 (Vote Outperform)Underperform Votes: 103 (Vote Underperform)Total Votes: 234MarketBeat's community ratings are surveys of what our community members think about Zymeworks and other stocks. Vote "Outperform" if you believe ZYME will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ZYME will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 12/18/2018 by MarketBeat.com StaffFeatured Article: Should you buy a closed-end mutual fund?